The combination of daratumumab with ibrutinib in CLL patients—untreated, refractory, or relapsed with a poor prognosis (e.g., 17p deletion and/or TP53 mutation)—is being studied in three active phase Ib/II clinical trials (NCT03447808, NCT03734198, NCT04230304). The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.